MEDTRONIC COREVALVE SYSTEM
Medtronic, Inc. · Decision date Jan 17, 2014
What did the FDA approve?
FDA records P130021 as an original PMA application. The recorded decision is approval, dated Jan 17, 2014.
FDA approval order statement
Approval for the Medtronic CoreValve System. This device is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis (aortic valve area ? 0.8 cm2, a mean aortic valve gradient of > 40 mmHg, or a peak aortic-jet velocity of > 4.0 m/s) and with native aortic annulus diameters between 18 and 29 mm who are judged by a heart team, including a cardiac surgeon, to be at extreme risk or inoperable for open surgical therapy (predicted risk of operative mortality and/or serious irreversible morbidity ? 50% at 30 days).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 17, 2014
Regulatory record facts
- Identifier
- P130021
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic, Inc.
- Product code
- NPT
- Decision code
- APPR
- Decision date
- Jan 17, 2014
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- Medtronic, Inc.
- Product code
- NPT
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P130021 received
Application receipt date recorded by FDA.
P130021 · FDA decision
APPR
P130021/S188 · Related supplement
Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti
Timeline entries are records held by MedtechLedger for P130021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 710 Medtronic Pkwy., Miinneapolis, MN, 55432
Sources and methodology
- Original FDA record: P130021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records